SY 201
Alternative Names: SY-201Latest Information Update: 01 Dec 2023
At a glance
- Originator Seinda Pharmaceutical
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Dry eyes
Most Recent Events
- 01 Dec 2023 Seinda Pharmaceutical completes a trial I/II trials in Dry eyes (In adults, In the elderly) in USA (Ophthalmic) (NCT05370495)
- 25 Jun 2022 Phase-I/II clinical trials in Dry eyes (In adults, In the elderly) in USA (Ophthalmic) (NCT05370495)
- 25 May 2022 SY 201 is available for licensing as of 18 May 2022. http://www.seindabio.com/